BusinessAdamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017By Nasdaq OMXFeb 22, 2018, 9:01 PM UTC
BusinessAdamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018By Nasdaq OMXFeb 13, 2018, 9:01 PM UTC
BusinessAdamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical PracticeBy Nasdaq OMXFeb 8, 2018, 2:01 PM UTC
BusinessVoyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s DiseaseBy Nasdaq OMXJan 23, 2018, 12:04 PM UTC
BusinessInternational Stem Cell Corporation Treated Real Estate Icon Kevin WeeksBy Nasdaq OMXJan 11, 2018, 1:45 PM UTC
BusinessInternational Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's DiseaseBy Nasdaq OMXNov 29, 2017, 1:30 PM UTC
BusinessVoyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D DayBy Nasdaq OMXNov 16, 2017, 9:45 PM UTC
BusinessNeuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative TechnologyBy Nasdaq OMXNov 14, 2017, 12:01 PM UTC
